{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-25-000074","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.001415+00:00","generated_at":"2026-05-17T22:25:01.844735+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ImmuneOnco reports 62% partial response rate in Phase 2 NSCLC trial of IMM2510 + chemo","bullets":["As of July 1, 2025, 33 patients dosed at 10 mg/kg; 21 efficacy-evaluable patients.","Partial responses in 62% of evaluable: 80% (8/10) squamous NSCLC, 46% (5/11) non-squamous.","No dose-limiting toxicities; only one TRAE leading to drug discontinuation; low-grade irAEs.","ImmuneOnco expects to present full data at a future medical conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-25-000074","json":"https://secwatch.observer/filing/0001789769-25-000074.json","markdown":"https://secwatch.observer/filing/0001789769-25-000074.md","text":"https://secwatch.observer/filing/0001789769-25-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000074/0001789769-25-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000074/til-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:25:01.844735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}